(Q41561740)

3 October 2017

1 reference

title

Therapy with cultured T cells: principles revisited (English)

1 reference

3 October 2017

Cheever MA

1

1 reference

PubMed ID

9255630

3 October 2017

Chen W

series ordinal

2

1 reference

3 October 2017

1 June 1997

1 reference

3 October 2017

Immunological Reviews

1 reference

3 October 2017

157

1 reference

3 October 2017

177-194

1 reference

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

3 October 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00982.X

Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00982.X

Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00982.X

Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00982.X

Characterization of apoptosis-resistant antigen-specific T cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00982.X

The induction of graft versus host disease in mice treated with cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00982.X

Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: results in 36 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00982.X

T cell suppressors of antitumor immunity. The production of Ly-1-,2+ suppressors of delayed sensitivity precedes the production of suppressors of protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00982.X

T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00982.X

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00982.X

FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00982.X

Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00982.X

Oncogenic proteins as tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1997.TB00982.X

10.1111/J.1600-065X.1997.TB00982.X

21 January 2018

Identifiers

DOI

1 reference

3 October 2017

1 reference

PubMed ID

9255630